insights_auto
Waarom is OPHLY gestegen 6,02%?
Meer informatiechevron_right
OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
US$Â 4,93
arrow_upward
+6,02%(+0,28) 1D
15 okt, 13:34:42 GMT-4 · USD
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor OPHLY genereren…
Openen
US$Â 4,96
Hoog
US$Â 4,96
Laag
US$Â 4,90
Beursw.
1,17Â bln.
Gem. vol.
61,54K
Volume
21,83K
52 wk hoog
US$Â 5,75
52 wk laag
US$Â 3,82
Bèta
0,21
Uitstaande aandelen
1,50Â mld.
Aantal medewerkers
4K
Openen
US$Â 4,96
Hoog
US$Â 4,96
Laag
US$Â 4,90
Beursw.
1,17Â bln.
Gem. vol.
61,54K
Volume
21,83K
52 wk hoog
US$Â 5,75
52 wk laag
US$Â 3,82
Bèta
0,21
Uitstaande aandelen
1,50Â mld.
Aantal medewerkers
4K
Nieuwsartikelen
Van webbronnen en nieuwspartners
MarketScreener Nederland
·
46 minuten geleden
S&P 500 en Nasdaq beperken verliezen nu AI-uitverkoop afzwakt; gezondheidszorg en basisconsumptiegoederen winnen
BeInCrypto
·
16 uur geleden
S&P 500 betreedt zijn sterkste seizoensperiode
MarketScreener Nederland
·
5 uur geleden
VS: index van de New York Fed overtreft de verwachtingen ruimschoots
Profiel
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Over Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
CEOGyo Sagara | Gyo Sagara
Medewerkers4,21K
Opgericht1717
HoofdkantoorOsaka, Osaka, Japan
Sector-
Websiteono-pharma.com